EMA’s CHMP adopts positive opinion for Pfizer’s and OPKO’s somatrogon for GHD treatment
A once-weekly long-acting recombinant human growth hormone, somatrogon is intended for treating children from three years of age and adolescents experiencing growth disturbance because of inadequate secretion of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.